drugset / Trial / NCT01910844
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes
NaSingle-groupOpen-labelTreatment
Summary
Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.
Timeline
- Start
- 2013-07
- Primary completion
- 2016-09
- Completion
- 2016-09
Outcome
Outcome not reported
Stopped: “Because of difficulties in recruting”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 150 mg | Oral |